Hayvan Deneyleri: In Vivo Denemelerin Bildirimi: ARRIVE Kılavuzu-Derleme

Çolak, Cemil; Parlakpınar, Hakan

doi:10.7247/jiumf.19.2.14

Cited by 18 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5377-3, 1996), Animal Ethics Committee." This animal experimental study was designed in observance with the ARRIVE guidelines (Colak and Parlakpinar, 2012).…”

Section: Methodsmentioning

confidence: 99%

Protective effects of melatonin against 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cardiac injury in rats

Sarıhan

Parlakpınar

Çiftçi

et al. 2015

European Journal of Pharmacology

View full text Add to dashboard Cite

“…5377-3, 1996), Animal Ethics Committee." This animal experimental study was designed in observance with the ARRIVE guidelines (Colak and Parlakpinar, 2012).…”

Section: Methodsmentioning

confidence: 99%

Protective effects of melatonin against 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cardiac injury in rats

Sarıhan

Parlakpınar

Çiftçi

et al. 2015

European Journal of Pharmacology

View full text Add to dashboard Cite

“…This animal experimental study was designed according to ARRIVE guidelines [22]. The protocol of this experimental study was approved by the Ethical Committee on Animal Research of Inonu University (Reference No.…”

Section: Animals and Experimental Proceduresmentioning

confidence: 99%

Protective Effects of Molsidomine Against Cisplatin-Induced Nephrotoxicity

Karakoc¹,

Altıntaş²,

Parlakpınar³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Cisplatin, an effective chemotherapeutic agent, is used for the treatment of several types of cancers. However, cisplatin has some severe side effects such as nephrotoxicity. On the other hand, molsidomine, a NO donor, has anti-oxidative and vasodilator effects. Objectives. The aim of this study was to estimate the protective effects of molsidomine on cisplatin-induced nephrotoxicity. Material and Methods. Thirty-two rats were randomly divided into 4 groups as follows: (1) control; (2) received a single-dose intraperitoneal (i.p.) injection of 5 mg/kg cisplatin; (3) received single i.p. dose of molsidomine (4 mg/kg/day) for 3 consecutive days before cisplatin treatment; (4) received single i.p. dose of molsidomine (4 mg/kg/day) for 3 consecutive days. The specific biochemical markers, including antioxidants, and the histopathological alterations were evaluated. Results. Cisplatin significantly increased malondialdehyde (MDA) and myeloperoxidase (MPO) levels and decreased glutathione peroxidase (GPX) level. Molsidomine significantly decreased MPO level nearly to control level; however, its ameliorating effects on MDA, SOD, CAT and GPX did not reach to significant levels. Cisplatin-induced elevation of blood-urea-nitrogen and serum-creatinine were diminished after molsidomine administration. Cisplatin also induced severe tubular degeneration, nuclear condensation, apoptosis and scattered patchy inflammation in the histological examination. Molsidomine improved all of these histological damages. Conclusions. In this study, the beneficial effect of molsidomine against cisplatin nephrotoxicity has been evaluated for the first time (Adv Clin Exp Med 2015, 24, 4, 585-593).

show abstract

“…15 Bu deneysel çalışma için İnönü Üniversitesi Deney Hayvanları Etik Kurulu onayı (Protokol no: 2015/A-101) alındı. Bu çalışma "Guide for the Care and Use of the Laboratory Animals" prensipleri doğrultusunda yapılarak hayvan hakları korundu.…”

Section: Gereç Ve Yöntemlerunclassified